New York, Jan 22, 2026, 13:19 EST — Regular session
- Shares of Regencell Bioscience surged roughly 37%, bouncing about $10 from their lowest to highest point during the session
- Since the company’s Oct. 31 annual report, there have been no new SEC filings, offering little fresh news to support the move
- Traders are eyeing any new disclosures and if the gains can stick through the 4 p.m. close
Shares of Regencell Bioscience Holdings Limited jumped roughly 37% to $29.98 in afternoon trading Thursday, rebounding sharply from earlier dips. The stock swung between $20.91 and $30.78, with around 1 million shares changing hands by 1:19 p.m. EST.
This move stands out because it follows a sharp drop in the opposite direction. Regencell shares fell 9.9% on Wednesday, closing at $21.91, highlighting the stop-start pattern that has made the stock tough to hold onto. Barron’s
Thursday’s surge didn’t come with any fresh company filings on the SEC’s EDGAR platform. The latest Regencell document posted there is still its annual report from Oct. 31, offering traders no new data aside from the price action itself. SEC
The stock started at $21.68, dipped below yesterday’s close, then surged sharply. It was last seen up $8.07 for the day.
Hong Kong-based Regencell is working on Traditional Chinese Medicine treatments targeting neurocognitive disorders like ADHD and autism. In a filing from June 2025, the company announced its board approved a 38-for-1 forward stock split, describing the move as a way to “enhance liquidity” and improve share accessibility for investors.
A stock split boosts the total shares outstanding but lowers the price per share, leaving the company’s overall market value unchanged. The latest annual report also revealed that Regencell received a subpoena and correspondence from the U.S. Department of Justice, which is “conducting an investigation” into trading activity involving its ordinary shares. SEC
The risk here is that a momentum-driven move can reverse sharply, especially when the stock is already experiencing wide intraday swings. Earlier this month, shares triggered a volatility pause under the market’s “limit up-limit down” rules—an automatic circuit breaker designed to curb extreme price jumps. NASDAQ Trader
Investors are scouring for clues to explain the sudden move — a new filing, a statement, or a change in trading dynamics. Attention will likely stay fixed on volume, spreads, and how quickly prices reverse.
All eyes now on whether Regencell can maintain its gains through the 4 p.m. EST close. Traders will also be on alert for any company updates or SEC filings after the bell that might shift the narrative.
